Loading…
Loading…
BMY · NYSE · Healthcare
“With a P/E of 17.1 against modest pharmaceutical growth prospects, BMY appears reasonably valued but lacks the compelling margin of safety prudent investors should demand.”
— In the voice of Graham
Project future earnings using analyst estimates and historical growth rates. Model 5-year earnings trajectories.
Market Cap
$120.86B
P/E Ratio
17.13
Forward P/E
—
EPS
$3.47
PEG Ratio
0.01
Book Value
$9.07
Dividend Yield
4.17%
Profit Margin
14.64%
ROE
38.19%
Use the interactive growth projection with pre-loaded data for Bristol-Myers Squibb Company. Adjust discount rates, growth assumptions, and projection horizons to model different scenarios.
Pre-loaded inputs for BMY: